Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab–interleukin 17A (IL-17A) drug-target complex. These sequence-defined antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for brentuximab vedotin, secukinumab, and their biosimilars.
Bio-Rad’s anti-brentuximab vedotin and anti-secukinumab inhibitory antibodies are available in Fab (fragment antigen-binding) and fully human IgG1 formats with different affinities. The antibodies can be used to develop PK bridging ELISAs to measure free drug or as a surrogate positive control or reference standard in an ADA assay.
Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma by selectively targeting tumor cells expressing the CD30 antigen. The four new anti-brentuximab vedotin antibodies are specific to the brentuximab antibody alone, as well as when it is conjugated to the toxin monomethyl auristatin E.
Secukinumab binds to IL-17A, resulting in inhibition of the patient’s inflammatory response in several diseases, including ankylosing spondylitis, psoriasis, and psoriatic arthritis. In addition to the four new inhibitory anti-secukinumab antibodies, Bio-Rad also offers the antibody specific to the anti-secukinumab–IL-17A complex. This antibody is suitable for use in a PK antigen capture assay, providing an alternative format to the PK bridging ELISA.
The recombinant antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply throughout the assay lifecycle.
“Bio-Rad’s range of ready-made and well-characterized anti-idiotypic antibodies keeps growing, offering researchers enhanced flexibility for the development of custom bioanalytical drug assays against a wide range of marketed biologic drugs,” said Jack Cooper, Bio-Rad Product Manager, Life Science Group. “Generated under stringent quality control for batch-to-batch consistency, these antibodies can produce translatable and reproducible results, ensuring assay reliability,” he said.
The anti-brentuximab vedotin and anti-secukinumab antibodies are approved for in vitro research purposes, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and for patient monitoring.